Fibrogen Stock Performance
| FGEN Stock | USD 8.78 0.08 0.92% |
The firm shows a Beta (market volatility) of -0.1, which means not very significant fluctuations relative to the market. As returns on the market increase, returns on owning FibroGen are expected to decrease at a much lower rate. During the bear market, FibroGen is likely to outperform the market. At this point, FibroGen has a negative expected return of -0.38%. Please make sure to confirm FibroGen's jensen alpha, accumulation distribution, relative strength index, as well as the relationship between the value at risk and day typical price , to decide if FibroGen performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days FibroGen has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's technical and fundamental indicators remain very healthy which may send shares a bit higher in February 2026. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
| Begin Period Cash Flow | 113.7 M | |
| Total Cashflows From Investing Activities | 126 M |
FibroGen Relative Risk vs. Return Landscape
If you would invest 1,173 in FibroGen on October 3, 2025 and sell it today you would lose (295.00) from holding FibroGen or give up 25.15% of portfolio value over 90 days. FibroGen is currently does not generate positive expected returns and assumes 4.0256% risk (volatility on return distribution) over the 90 days horizon. In different words, 36% of stocks are less volatile than FibroGen, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
FibroGen Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for FibroGen's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as FibroGen, and traders can use it to determine the average amount a FibroGen's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0948
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FGEN |
Based on monthly moving average FibroGen is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of FibroGen by adding FibroGen to a well-diversified portfolio.
FibroGen Fundamentals Growth
FibroGen Stock prices reflect investors' perceptions of the future prospects and financial health of FibroGen, and FibroGen fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on FibroGen Stock performance.
| Return On Equity | -10.16 | |||
| Return On Asset | -0.18 | |||
| Profit Margin | 25.99 % | |||
| Operating Margin | (4.99) % | |||
| Current Valuation | 85.89 M | |||
| Shares Outstanding | 4.05 M | |||
| Price To Earning | 97.67 X | |||
| Price To Book | 53.83 X | |||
| Price To Sales | 4.28 X | |||
| Revenue | 29.62 M | |||
| EBITDA | (142.43 M) | |||
| Cash And Equivalents | 438.13 M | |||
| Cash Per Share | 4.67 X | |||
| Total Debt | 90.17 M | |||
| Debt To Equity | 0.89 % | |||
| Book Value Per Share | (4.21) X | |||
| Cash Flow From Operations | (138 M) | |||
| Earnings Per Share | (12.85) X | |||
| Total Asset | 214.53 M | |||
| Retained Earnings | (1.89 B) | |||
| Current Asset | 200.56 M | |||
| Current Liabilities | 67.18 M | |||
About FibroGen Performance
By examining FibroGen's fundamental ratios, stakeholders can obtain critical insights into FibroGen's financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that FibroGen is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California. Fibrogen Inc operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 566 people.Things to note about FibroGen performance evaluation
Checking the ongoing alerts about FibroGen for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for FibroGen help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| FibroGen generated a negative expected return over the last 90 days | |
| FibroGen has high historical volatility and very poor performance | |
| FibroGen has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 29.62 M. Net Loss for the year was (47.58 M) with loss before overhead, payroll, taxes, and interest of (30.35 M). | |
| FibroGen currently holds about 438.13 M in cash with (138 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.67. |
- Analyzing FibroGen's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether FibroGen's stock is overvalued or undervalued compared to its peers.
- Examining FibroGen's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating FibroGen's management team can have a significant impact on its success or failure. Reviewing the track record and experience of FibroGen's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of FibroGen's stock. These opinions can provide insight into FibroGen's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in FibroGen. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. To learn how to invest in FibroGen Stock, please use our How to Invest in FibroGen guide.You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Stock space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of FibroGen. If investors know FibroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about FibroGen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of FibroGen is measured differently than its book value, which is the value of FibroGen that is recorded on the company's balance sheet. Investors also form their own opinion of FibroGen's value that differs from its market value or its book value, called intrinsic value, which is FibroGen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because FibroGen's market value can be influenced by many factors that don't directly affect FibroGen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between FibroGen's value and its price as these two are different measures arrived at by different means. Investors typically determine if FibroGen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, FibroGen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.